Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Halozyme Therapeutics and Ventana Medical Systems, a member of the Roche Group, announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's ...
read more
Wednesday, April 13, 2022
Halozyme Therapeutics, Inc. and Antares Pharma, Inc. have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was ...
read more
Monday, November 21, 2016
Halozyme Therapeutics announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target ...
read more
Halozyme Therapeutics announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.
read more
Halozyme Therapeutics has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO duties on June 15 and will work with Ramsay through a transition ...
read more
Halozyme Therapeutics has announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics...
read more
Halo Pharmaceutical, a rapidly growing Contract Development and Manufacturing Organization (CDMO) is very pleased to announce the appointment of Roberto Darienzo to the newly created position of Chief Operating Officer.
read more
Tuesday, October 14, 2025
Halo Pharma appointed Laurent Malgouyres as Site Director for its facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance.
read more
Tuesday, December 16, 2025
Halo Pharma is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve ...
read more
Halo Pharma announces the formation of its Pediatric Center of Excellence in support of the development and manufacture of dosage forms tailored for pediatric indications.
read more
ExxPharma Therapeutics and Halo Pharmaceutical have entered into a collaboration agreement to develop and manufacture drug products for customers of Halo and ExxPharma using ExxPharma's drug delivery systems and twin screw extrusion-based ...
read more
Wednesday, December 23, 2020
HALIX has signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.
read more
HALIX announced they have met their major milestone with the interim delivery of their new 6,700 m2 cGMP facility in Leiden Bio Science Park.
read more
Wednesday, April 15, 2020
HALIX has joined a consortium of partners to provide GMP manufacturing services supporting the large scale production of a COVID-19 vaccine being developed by the University’s Jenner Institute.
read more
Monday, November 25, 2019
HALIX has announced the opening of its new 6,700 m² cGMP facility at the Leiden Bio Science Park.
read more